Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P060022/S038

Akreos posterior chamber intraocular lens

Bausch + Lomb, Inc. · Decision date Sep 3, 2026

MEDTECHLEDGER EXPLANATIONP060022/S038

What did the FDA decide?

The FDA record P060022/S038 is a 30-day notice for the Akreos posterior chamber intraocular lens (product code HQL, Ophthalmic), submitted by Bausch & Lomb, Inc., with a decision dated 2026-09-03. The supplement reason is listed as a process change involving a manufacturer, sterilizer, packager or supplier. The stated scope, in the record's own words, is "the elimination of certain redundant post-coating incoming inspections for coated lens shuttles."

That statement does not specify which shuttles, how many inspections are removed, or what replacement controls, if any, apply. The source describes a manufacturing-process adjustment; it does not establish safety or clinical effectiveness, and it is not a new approval of the whole lens system. The S038 suffix ties the notice to PMA P060022, but the supplied fields give no further detail on the original approval's scope.

FDA approval order statement

the elimination of certain redundant post-coating incoming inspections for coated lens shuttles
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Sep 3, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P060022/S038
Regulatory pathway
PMA supplement
Product code
HQL
Decision code
OK30
Decision date
Sep 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: intraocular lens.

Product code
HQL
FDA device class
3

For the original device and its historical approval scope, see PMA P060022. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P060022 · Original PMA

    AKREOS POSTERIOR CHAMBER INTRAOCULAR LENS,MODEL ADAPT

  2. P060022/S038 received

    Application receipt date recorded by FDA.

  3. P060022/S038 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P060022. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P060022

Product / regulatory recordCompanyPathwayDecision dateSource
Bausch + Lomb, Inc.PMA approvalSep 5, 2008FDA

Explore the linked device profile

Other records with product code HQL

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bausch + Lomb, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
50 Technology Dr., Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records